Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals

Key Inclusion Criteria: * A clinical diagnosis of acute ischemic stroke in the MCA territory (PCA and/or ACA territory involvement in addition to primary MCA territory stroke is acceptable). * Prior to stroke, no disability, or no significant disability despite symptoms (able to carry out all usual duties and activities). * A baseline DWI lesion between 82 and 300 cm3 on MRI. * Patients treated with IV rtPA should meet established criteria for IV rtPA administration in the 0-3 and 3-4.5 hr time periods at the time of rtPA administration (if rtPA is administered in the 3-4.5 hr time window, the NIHSS must be ≤ 25 at the time of rtPA administration). * The time to the start of infusion of Study Drug must be ≤ 10 hours after time of symptom onset, if known, or the time last seen well \[termed "time last known at neurologic baseline" (TLK@B)\]. * Provision of written informed consent by a legally authorized representative according to institutional guidelines and national regulations. Key Exclusion Criteria: * Commitment to decompressive craniectomy (DC) prior to enrollment, or following enrollment and prior to start of Study Drug. * Treatment with intra-arterial (IA) rtPA or by mechanical means for clot disruption. * Patients unable to tolerate MRI scanning, e.g. those with pacemakers or automatic defibrillators. * Evidence (clinical or imaging) of concurrent infarction in the contralateral hemisphere deemed by the investigator to be sufficiently serious so as to affect funct…